Postoperative Follow-up Programs Improve Survival in Curatively Resected Gastric and Junctional Cancer Patients: a Propensity Score Matched Analysis
Overview
Oncology
Authors
Affiliations
Background: To date there is no evidence that more intensive follow-up after surgery for esophagogastric adenocarcinoma translates into improved survival. This study aimed to evaluate the impact of standardized surveillance by a specialized center after resection on survival.
Methods: Data of 587 patients were analyzed who underwent curative surgery for esophagogastric adenocarcinoma in our institution. Based on their postoperative surveillance, patients were assigned to either standardized follow-up (SFU) by the National Center for Tumor Diseases (SFU group) or individual follow-up by other physicians (non-SFU group). Propensity score matching (PSM) was performed to compensate for heterogeneity between groups. Groups were compared regarding clinicopathological findings, recurrence, and impact on survival before and after PSM.
Results: Of 587 patients, 32.7% were in the SFU and 67.3% in the non-SFU group. Recurrence occurred in 39.4% of patients and 92.6% within the first 3 years; 73.6% were treated, and of those 17.1% underwent resection. In recurrent patients overall and post-recurrence survival (OS/PRS) was influenced by diagnostic tools (p < 0.05), treatment (p ≤ 0.001), and resection of recurrence (p ≤ 0.001). Standardized follow-up significantly improved OS (84.9 vs. 38.4 months, p = 0.040) in matched analysis and was an independent positive predictor of OS before and after PSM (p = 0.034/0.013, respectively).
Conclusion: After PSM, standardized follow-up by a specialized center significantly improved OS. Cross-sectional imaging and treatment of recurrence were associated with better outcome. Regular follow-up by cross-sectional imaging especially during the first 3 years should be recommended by national guidelines, since early detection might help select patients for treatment of recurrence and even resection in few designated cases.
Wang J, Chen R, Tang J J Robot Surg. 2024; 18(1):405.
PMID: 39527138 DOI: 10.1007/s11701-024-02159-3.
Zhu Y, Lu Y, Zhu Y, Ren X, Deng Q, Yang M Sci Rep. 2024; 14(1):26393.
PMID: 39488565 PMC: 11531471. DOI: 10.1038/s41598-024-76763-6.
Rompen I, Schutte I, Crnovrsanin N, Schiefer S, Billeter A, Haag G Ann Surg Oncol. 2024; 31(10):6900-6908.
PMID: 38969858 PMC: 11413044. DOI: 10.1245/s10434-024-15721-y.
Aiolfi A, Bona D, Cali M, Manara M, Rausa E, Bonitta G J Clin Med. 2024; 13(10).
PMID: 38792391 PMC: 11122204. DOI: 10.3390/jcm13102849.
Russell K, Forbes C, Qi S, Link C, Watson L, Deiure A Cancers (Basel). 2024; 16(7).
PMID: 38610971 PMC: 11011194. DOI: 10.3390/cancers16071294.